MYLAN 9 4 (Carbidopa and levodopa extended release 50 mg / 200 mg)
Pill imprint MYLAN 9 4 has been identified as Carbidopa and levodopa extended release 50 mg / 200 mg.
Carbidopa/levodopa is used in the treatment of restless legs syndrome; parkinson's disease; neuroleptic malignant syndrome; gtp-ch deficiency and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 50 mg / 200 mg is classified as a Schedule N controlled substance under the Controlled Substance Act (CSA).
- 50 mg / 200 mg
- 13.00 mm
- Elliptical / Oval
- Prescription only
FD&C Red No. 40
|NDC Code||Manufacturer / Repackager|
|51079-0923||UDL Laboratories Inc|
|68258-9026||Dispensing Solutions Inc. (repackager)|
|67544-0672||Prepak Systems Inc (repackager)|
Note: Inactive ingredients may vary.
More about carbidopa/levodopa
- Carbidopa and levodopa
- Carbidopa and levodopa extended-release capsules
- Carbidopa and levodopa orally disintegrating tablets
- Carbidopa and levodopa suspension
- Carbidopa and levodopa sustained-release tablets
- More (6) »
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2015 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.